Avacta Group PLC (AVCT) - Total Assets
Based on the latest financial reports, Avacta Group PLC (AVCT) holds total assets worth GBX29.24 Million GBX (≈ $3.56K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See AVCT equity financing ratio to measure how much of total assets are equity-financed.
Avacta Group PLC - Total Assets Trend (2001–2024)
This chart illustrates how Avacta Group PLC's total assets have evolved over time, based on quarterly financial data. Check AVCT goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Avacta Group PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Avacta Group PLC's total assets of GBX29.24 Million consist of 83.3% current assets and 16.7% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 26.7% |
| Accounts Receivable | GBX3.38 Million | 7.0% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX305.00K | 0.6% |
| Goodwill | GBX1.54 Million | 3.2% |
Asset Composition Trend (2001–2024)
This chart illustrates how Avacta Group PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Avacta Group PLC stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Avacta Group PLC's current assets represent 83.3% of total assets in 2024, an increase from 11.3% in 2001.
- Cash Position: Cash and equivalents constituted 26.7% of total assets in 2024, up from 5.7% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 7.0% of total assets.
Avacta Group PLC Competitors by Total Assets
Key competitors of Avacta Group PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Avacta Group PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.79 | 1.29 | 19.28 |
| Quick Ratio | 0.79 | 1.21 | 19.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX-5.91 Million | GBX10.18 Million | GBX57.28 Million |
Avacta Group PLC - Advanced Valuation Insights
This section examines the relationship between Avacta Group PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1686.71 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -34.0% |
| Total Assets | GBX48.27 Million |
| Market Capitalization | $3.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values Avacta Group PLC's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Avacta Group PLC's assets decreased by 34.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Avacta Group PLC (2001–2024)
The table below shows the annual total assets of Avacta Group PLC from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX48.27 Million ≈ $5.87K |
-34.05% |
| 2023-12-31 | GBX73.19 Million ≈ $8.91K |
-21.00% |
| 2022-12-31 | GBX92.65 Million ≈ $11.27K |
+97.12% |
| 2021-12-31 | GBX47.00 Million ≈ $5.72K |
-30.33% |
| 2020-12-31 | GBX67.46 Million ≈ $8.21K |
+137.46% |
| 2019-12-31 | GBX28.41 Million ≈ $3.46K |
+21.14% |
| 2018-07-31 | GBX23.45 Million ≈ $2.85K |
-25.67% |
| 2017-07-31 | GBX31.55 Million ≈ $3.84K |
-15.98% |
| 2016-07-31 | GBX37.55 Million ≈ $4.57K |
+75.46% |
| 2015-07-31 | GBX21.40 Million ≈ $2.60K |
-31.07% |
| 2014-07-31 | GBX31.05 Million ≈ $3.78K |
+75.87% |
| 2013-07-31 | GBX17.66 Million ≈ $2.15K |
-4.51% |
| 2012-07-31 | GBX18.49 Million ≈ $2.25K |
+49.88% |
| 2011-07-31 | GBX12.34 Million ≈ $1.50K |
+9.92% |
| 2010-07-31 | GBX11.22 Million ≈ $1.37K |
+23.93% |
| 2009-07-31 | GBX9.05 Million ≈ $1.10K |
+76.03% |
| 2008-07-31 | GBX5.14 Million ≈ $625.88 |
+80.81% |
| 2007-07-31 | GBX2.85 Million ≈ $346.15 |
+8521.21% |
| 2006-04-30 | GBX33.00K ≈ $4.02 |
-84.65% |
| 2005-04-30 | GBX215.00K ≈ $26.16 |
-84.44% |
| 2004-04-30 | GBX1.38 Million ≈ $168.15 |
+659.34% |
| 2003-04-30 | GBX182.00K ≈ $22.14 |
+1.68% |
| 2002-04-30 | GBX179.00K ≈ $21.78 |
-15.57% |
| 2001-04-30 | GBX212.00K ≈ $25.79 |
-- |
About Avacta Group PLC
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatec… Read more